Nykode Therapeutics AS (FRA:5VB) Interest Expense: €-0.10 Mil (TTM As of Mar. 2026)


FRA:5VB Nykode Therapeutics AS FRA:5VB
37 GF Score
Price €0.25
GF Value €0.49
Valuation Possible Value Trap
! 2 Warning Signs
View Full Analysis

What is Nykode Therapeutics AS Interest Expense?

Nykode Therapeutics AS FRA:5VB -0.61% 37 Interest Expense is €-0.10 Mil as of Mar. 2026. GuruFocus rates FRA:5VB with a GF Score™ of 37/100 and a GF Value™ of €0.49 (Possible Value Trap). The stock has 2 warning signs investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Nykode Therapeutics AS's interest expense for the three months ended in Mar. 2026 was € -0.02 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2026 was €-0.10 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Nykode Therapeutics AS's Operating Income for the three months ended in Mar. 2026 was € -5.65 Mil. Nykode Therapeutics AS's Interest Expense for the three months ended in Mar. 2026 was € -0.02 Mil. Nykode Therapeutics AS did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Nykode Therapeutics AS  (FRA:5VB) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Nykode Therapeutics AS's Interest Expense for the three months ended in Mar. 2026 was €-0.02 Mil. Its Operating Income for the three months ended in Mar. 2026 was €-5.65 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2026 was €0.89 Mil.

Nykode Therapeutics AS's Interest Coverage for the quarter that ended in Mar. 2026 is calculated as

Nykode Therapeutics AS did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Nykode Therapeutics AS Interest Expense Historical Data

* Premium members only.

The historical data trend for Nykode Therapeutics AS's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nykode Therapeutics AS Interest Expense Chart

Nykode Therapeutics AS Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Interest Expense
Get a 7-Day Free Trial Premium Member Only -0.12 -0.23 -0.21 -0.18 -0.11

Nykode Therapeutics AS Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.03 -0.03 -0.03 -0.03 -0.02
FRA:5VB
37GF Score
Nykode Therapeutics AS FRA:5VB
Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nykode Therapeutics AS Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.10 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Expense →
What does a Interest Expense of €-0.10 Mil mean?
Nykode Therapeutics AS (FRA:5VB) has a Interest Expense of €-0.10 Mil as of Mar. 2026. Interest Expense is the amount a company pays on its long-term debt. View historical data on Nykode Therapeutics AS and its competitors.
Is Nykode Therapeutics AS's Interest Expense too high?
Nykode Therapeutics AS's current Interest Expense is €-0.10 Mil. Overall, Nykode Therapeutics AS has a GF Score™ of 37/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Nykode Therapeutics AS's Interest Expense compare to VRTX and REGN?
Nykode Therapeutics AS's Interest Expense of €-0.10 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Biotechnology company?
A good Interest Expense depends on the Biotechnology industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Nykode Therapeutics AS and its competitors. Nykode Therapeutics AS's current Interest Expense is €-0.10 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nykode Therapeutics AS stock overvalued right now?
Based on GuruFocus' analysis, Nykode Therapeutics AS (FRA:5VB) is currently considered Possible Value Trap. The stock's GF Value™ is €0.49, compared to a current price of €0.25 — trading 50% below its estimated fair value. The current Interest Expense is €-0.10 Mil. Nykode Therapeutics AS's overall GF Score™ is 37/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For Nykode Therapeutics AS (FRA:5VB), the current Interest Expense is €-0.10 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Nykode Therapeutics AS (FRA:5VB) Overvalued in 2026?

Based on GuruFocus' analysis, Nykode Therapeutics AS stock appears to be undervalued. The current stock price of €0.25 is trading 50% below its estimated GF Value™ of €0.49. GuruFocus considers Nykode Therapeutics AS to be Possible Value Trap.

Key valuation signals for FRA:5VB:

  • Interest Expense: €-0.10 Mil
  • GF Value™: €0.49 vs. price of €0.25 (50% below fair value)
  • GF Score™: 37/100 with 2 warning signs

No single metric tells the full story. See the FRA:5VB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Nykode Therapeutics AS Business Description

Address Gaustadalleen 21, Oslo Research Park, Oslo, NOR, 0349
Nykode Therapeutics AS is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immunotherapies. The company is developing individualized cancer neoantigen vaccines and is using the Vaccibody technology to generate therapeutics to treat cancers with a high unmet medical need using it's modular immunotherapy technology, specifically targeting antigens to Antigen Presenting Cells, which are essential for inducing rapid and long-lasting immune responses. It operates in United States of America.
37GF Score

Get the complete analysis for FRA:5VB

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.25
Price
€0.49
GF Value